# Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

Study · id `cardio:ct-nct01729559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01729559](<https://clinicaltrials.gov/study/NCT01729559>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01729559

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 495 participants.

## Technical summary

Registry record NCT01729559. Randomized; single masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2016-07-18.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 495 participants (enrolled count; ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Start date: 2012-11 (registry gives no type) (ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Results first posted: 2016-07-18 (ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01729559, source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01729559-2016-07-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
- Condition: Venous Thromboembolic Disease
- Condition: Deep Vein Thrombosis
- Condition: Pulmonary Embolism
- Intervention (Drug): 5000 Units unfractionated Heparin Q 8 hr
- Intervention (Drug): 30mg enoxaparin Q12 hr
- Lead sponsor: Scripps Health
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Scripps Health (`cardio:org-scripps-health`)

## Provenance

Content hash: 856d9686db33c4e7ed7d5667128a4cd230bdf6f04da63fe732c50cda6e98bf25
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
